Sales to China doubled year-on-year while management admits they 'have to follow restrictions' they refuse to quantify.
Thesis: Screen is the ultimate pick-and-shovel play with a dirty secret. They own the cleaning bottleneck—essential for every advanced node step—giving them 23% margins in SPE. The street fears the China cliff (sales doubled), but the backlog is firm and non-cancellable. You're buying a monopoly on yield enhancement priced like a cyclical equipment grinder.
Verdict: LONG — Conviction: MEDIUM
Catalyst: H2 2024 DRAM spending restart. Management confirmed DRAM investment picks up in the second half, which diversifies the revenue mix away from the China-heavy foundry spend.
Key Risk: Export controls are the sword of Damocles. With China sales doubling, a sudden regulatory tightening isn't just a headwinds, it's a decapitation of their growth engine.
The Tell: When asked about the 30% margin target, CEO Kondo snapped, 'I have no comment. Sorry about that.' right after saying he wants it personally. It reveals the internal tension between public guidance (conservative) and internal mandates (aggressive).
Friction Level: MODERATE_FRICTION — The durability of China revenue. Bulls see a backlog fortress; Bears see a regulatory cliff that management is actively dodging questions about.
Report not found
The report data is no longer available. Please return to the archive.